Meeting
2023 ASCO Genitourinary Cancers Symposium
Patient characteristics, treatment patterns and outcomes for patients with renal cell carcinoma in England: A retrospective cohort study using data from the National Cancer Registry and treatment and hospital data.
Authors
Prantik Das
University Hospitals of Derby and Burton NHS Foundation Trust, University of Nottingham, School of Medicine, Nottingham, United Kingdom
Prantik Das , Andrew Clark , Beth Nordstrom , Alison Booth , Poonam Dhokia , Robert Carroll , Luis Vaz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 639)
DOI
10.1200/JCO.2023.41.6_suppl.639
Abstract #
639
Poster Bd #
F9
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
First Author: Bradley Alexander McGregor
Poster
2023 ASCO Genitourinary Cancers Symposium
Immunohistochemical (IHC) subtypes of metastatic bladder cancer (mBC) using GATA3 and CK5/6.
First Author: Ariel Ann Nelson
Poster
2023 ASCO Genitourinary Cancers Symposium
Patient perspectives on the impact of immune therapy on comorbid conditions in kidney cancer.
First Author: Ulka N. Vaishampayan
Poster
2022 ASCO Annual Meeting
Real-world treatment patterns and outcomes among patients (pts) with second-line (2L) and third-line (3L) metastatic triple-negative breast cancer (mTNBC) in England using the Cancer Analysis System (CAS).
First Author: Lawrence Chang